XML 42 R29.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Information (Tables)
12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Information

The following table sets forth the Company’s segment information (in thousands):

 

 

Year Ended December 31,

 

 

 

2025

 

 

2024

 

 

2023

 

Direct external expenses by program:

 

 

 

 

 

 

 

 

 

Zidesamtinib

 

$

59,519

 

 

$

62,110

 

 

$

27,878

 

Neladalkib

 

 

105,446

 

 

 

67,778

 

 

 

31,894

 

NVL-330

 

 

21,819

 

 

 

8,293

 

 

 

10,634

 

Discovery programs

 

 

11,875

 

 

 

9,178

 

 

 

8,586

 

Personnel-related expenses

 

 

73,163

 

 

 

44,121

 

 

 

29,225

 

Stock-based compensation expense

 

 

86,502

 

 

 

60,579

 

 

 

25,563

 

General and administrative professional and consultant fees

 

 

15,033

 

 

 

10,854

 

 

 

6,423

 

Change in fair value of related party revenue share liability

 

 

55,220

 

 

 

17,940

 

 

 

 

Interest income

 

 

(44,794

)

 

 

(38,372

)

 

 

(23,277

)

Other segment items(1)

 

 

41,009

 

 

 

17,511

 

 

 

9,293

 

Income tax provision

 

 

585

 

 

 

764

 

 

 

 

Consolidated net loss

 

$

(425,377

)

 

$

(260,756

)

 

$

(126,219

)

 

(1) Other segment items included in consolidated net loss include expenses for commercialization preparation activities, research and development consulting services, information technology, insurance, employee recruitment and other miscellaneous activities.